CytRx Corp. buy melinda
Start price
11.05.17
/
50%
€2.41
Target price
18.05.17
€3.25
Performance (%)
14.13%
End price
18.05.17
€2.75
Summary
This prediction ended on 18.05.17 with a price of €2.75. The BUY prediction by melinda finished with a performance of 14.13%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | -1.020% | -1.140% | 1.595% | 50.955% |
| iShares Nasdaq 100 | -2.520% | -5.253% | 26.601% | 82.154% |
| iShares Nikkei 225® | -4.443% | -10.161% | 53.012% | 68.736% |
| iShares S&P 500 | -1.226% | -0.040% | 21.556% | 65.370% |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Aldoxorubicine mit Doxorubicin
Krebs Weichteilsarkom feuerfester Krebs
(Vom Mitglied beendet)


